• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Dr. Reddy's Laboratories Launches Valsartan Tablets, USP in the U.S. Market

AmericanPharmaceuticalReviewDecember 10, 2021

Tag: Valsartan , USP , Tablets

Dr. Reddy’s Laboratories Ltd. announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Diovan® brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

Dr. Reddy’s Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.

Previous:MHI RJ Aviation Group and Aero HygenX sign a cooperation agreement for Marketing and Distribution of RAY UV-C Robot

Next:Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Dr. Reddy's Laboratories Launches Valsartan Tablets, USP in the U.S. Market | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Trimebutine maleate for suspension

Trimebutine maleate for suspension
Felodipine Sustained-Release Tablets 2.5mg, 5mg, 10mg

Felodipine Sustained-Release Tablets 2.5mg, 5mg, 10mg
Cefpodoxime Proxetil Tablets

Cefpodoxime Proxetil Tablets
Oseltamivir phosphate suspension

Oseltamivir phosphate suspension
Amoxicillin dispersible tablets

Amoxicillin dispersible tablets
Pyrotinib Maleate Tablets

Pyrotinib Maleate Tablets
Atorvastatin Calcium Tablets

Atorvastatin Calcium Tablets
Penicillin   G potassium Tablets 

Penicillin   G potassium Tablets 
Buspirone HCl

Buspirone HCl
Cotrimoxazole Tablet BP/ USP 800mg/160mg

Cotrimoxazole Tablet BP/ USP 800mg/160mg

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service